CTLA4 and cancer: mAbs that block cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed cell death protein 1 (PD1), and programmed cell death ligand 1 (PDL1) represent the predominant modalities for cancer immunotherapy and have revolutionized the cancer treatment paradigm in recent years3,4.